Cerebrospinal Fluid Biomarkers in Dementia Patients with Cerebral Amyloid Angiopathy.
Chin Med Sci J
; 30(3): 170-3, 2015 Sep.
Article
em En
| MEDLINE
| ID: mdl-26564416
ABSTRACT
OBJECTIVE:
To study the changes of biomarkers in cerebrospinal fluid (CSF) in cerebral amyloid angiopathy (CAA) dementia and Alzheimer(')s disease.METHODS:
Levels of amyloid protein ß (Aß42, Aß40) and phosphorylated Tau-protein (P-tau) in CSF and ratio of Aß42/Aß40 were tested in 5 cases with CAA dementia and 20 cases with Alzheimer's disease collected at Peking Union Medical College Hospital from December 2001 to March 2011.RESULTS:
The levels of Aß42, Aß40, and P-tau in CSF and ratio of Aß42/Aß40 were (660.4 ± 265.2) ng/L, (7111.0 ± 1033.4) ng/L, (71.8 ± 51.5) ng/L, and 0.077 ± 0.033, respectively in CAA dementia and (663.6 ± 365.6) ng/L, (5115.0 ± 2931.1) ng/L, (47.7 ± 38.8) ng/L, and 0.192 ± 0.140, respectively in Alzheimer's disease patients. There were no statistically significant differences between CAA dementia and Alzheimer's disease in terms of these CSF biomarkers (all P>0.05).CONCLUSION:
Measurements of CSF biomarkers may not be helpful in differential diagnosis of CAA and Alzheimer's disease.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Biomarcadores
/
Angiopatia Amiloide Cerebral
/
Demência
Limite:
Aged
/
Aged80
/
Humans
/
Male
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article